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Abstract 
Conformational studies of C2 symmetric peptidomimetics with identical peptide strands attached 
on both sides of 2,5-anhydro sugar diacid and 2,5-anhydro sugar diamine scaffolds revealed the 
presence of nine-membered pseudo β-turns in the sugar diacid based molecules consisting of 
identical intramolecular hydrogen bonds at the two ends between the AA2NH and sugarOH. 
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Introduction 
 
We developed and studied a new class of compounds 1-8 (Figure 1), as potential HIV-protease 
inhibitors that were based on carbohydrate peptide hybrid structures.1 In this strategy, identical 
peptide chains were attached on both sides of C2 symmetric carbohydrate based scaffolds, 
leading to the formation of C2-symmetric peptiodomimetics.2 Carbohydrate based molecular 
designs are increasingly drawing attention of chemists.3 Detailed studies on the development of 
new HIV-1 protease inhibitors based on C2 symmetric scaffolds and acyclic carbohydrates have 
recently been reported.4 It is also being increasingly felt that small molecule protease inhibitors 
need to have restricted degrees of freedom which is evident from the success of cyclic urea based  
inhibitors.5 This prompted us to study cyclic carbohydrate based core foundations as 
conformationally rigid scaffolds to build a new class of molecular framework as potential 
protease inhibitors. 
Two different types of cyclic carbohydrate frameworks of sugar diacid and sugar diamine 
were employed in our design. These molecules are 2,5-anhydro-D-idaric acid 9 (Idac), 1,6-
diamino-2,5-anhydro-1,6-dideoxy-D-iditol 10 (Idam) and 1,6-diamino-2,5-anhydro-1,6-dideoxy-
D-mannitol 11 (Mdam). Attachment of identical peptide strands on both sides of these scaffolds 
led to the formation of peptidomimetic compounds 1-8, whose syntheses were reported earlier.1 
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The conformational study of 1 was carried out in detail and revealed a C2 symmetric structure 
with a nine-membered pseudo β-turn consisting of identical intramolecular hydrogen bonds at the 
two ends between the LeuNH and sugarOH.6 A very small temperature coefficient for the 
LeuNH chemical shift (∆δ/∆T = –1.2 ppb.K–1) was observed in DMSO-d6. The presence of two 
‘cis-β-hydroxycarboxyl’ moieties, the core structural motif believed to be responsible for such 
intramolecular H-bonds, on two sides of the tetrahydrofuran ring, nucleated identical β-turn-like 
structures in 1 at both ends. In this paper, we describe detailed conformational analysis of 
compounds 2-8 achieved by various NMR techniques, which revealed that while all these 
molecules had C2 symmetric structures, only the sugar diacid based compounds 2-4, especially 
those with free hydroxyl groups on the sugar ring, had the propensity to form nine-membered 
pseudo β-turn like structures containing intramolecular hydrogen bonds between AA2NH → 
sugarOH. This supports further the earlier observations that free hydroxyl groups on sugar rings 
prevent furanoid sugar amino acid based short linear peptides to adopt regular β-turn structures 
as these hydroxyl groups themselves act as hydrogen bond acceptors.3a,6 
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Figure 1 
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Results and Discussion 
 
Conformational analysis. NMR studies  
NMR studies of compounds 2, 3, 5-8 were carried out in DMSO-d6. The solvent used for 4 was 
CDCl3, although its variable temperature studies (VT) were done in DMSO-d6. The NMR 
spectra of the peptides described here were quite well resolved, and most of the spectral 
parameters could be obtained easily for compounds 2-8. Assignments were carried out with the 
help of total correlation spectroscopy (TOCSY), rotating frame nuclear Overhauser effect 
spectroscopy (ROESY) experiments. The cross peak signals in ROESY spectra were used for 
obtaining the restraints in MD calculations.  
Variable temperature studies. Information on the participation of amide protons of compounds 
2-8 in intramolecular hydrogen bonding was obtained by variable temperature studies carried out 
between 30– 70 °C in DMSO-d6.7 The temperature coefficients ∆δ/∆T obtained for various 
amide protons in these molecules are listed in Table 1. Hydrogenation of compound 2 gave a 
complex mixture of products and so its structure was studied in the Bn-protected form, which 
showed high temperature coefficients for the amide proton chemical shifts (Table 1), indicating 
absence of any H-bonding. The temperature coefficient ∆δ/∆T of LeuNH peak in 3 was –2.3 
ppb.K–1 (Figure 2) indicating its significant propensity to form an intramolecularly hydrogen 
bonded structure.7 Further support for such a H-bonded structure came from the appearance of 
the OH signal at an appreciable downfield at 5.96 ppm. In peptide 4, the propensity of the 
formation of an intramolecular H-bond was less compared to 3, as indicated by the relatively 
higher value of ∆δ/∆T of –2.8 ppb.K–1 for its LeuNH. The decrease in the H-bond forming 
capability may be due to the replacement of the ring OH groups in 3 by OBn in 4. Further, the 
diamine peptidomimetics 5-8 showed large magnitudes of ∆δ/∆T indicating the absence of any 
intramolecular H-bonding in these molecules. Further, the OH protons in these compounds 
resonated upfield as compared to 3 at δ 5.06, 5.05, 5.18, and 5.17 for 5, 6, 7, and 8, respectively, 
indicating that they were not involved in H-bonding.3j 
 
Table 1. Temperature coefficients (–ppb.K–1) data for Peptides 2-8 in DMSO-d6 
Peptides Phe Leu/Val Ala 
2 3.2 4.5 - 
3 5.9 2.3 5.0 
4 5.2 2.8 3.7 
5 4.2 7.7 - 
6 4.3 8.3 - 
7 3.5 8.0 - 
8 4.0 8.3 - 
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Figure 2. Amide regions of the 1H NMR spectra recorded between 30 – 70 °C for peptide 3. 
 
Conformational analysis of 2. Perfect C2 symmetry was observed in 2 showing signals 
distinctly only from half of the molecule in its NMR spectrum in DMSO-d6. In the ROESY 
spectrum of 2 in DMSO-d6, the characteristic NOE like PheNH ↔ IdacC3H and the sequential 
NOEs like ArNH ↔ ValCαH, ValNH ↔ PheCαH, PheNH ↔ IdacC2H were observed (Figure 
3). The large magnitudes of ∆δ/∆T of the amide protons indicate that, due to the bulky Bn-
protecting groups as well the sterically crowded Val side-chains, the ValNH did not participate 
in H-bonding with the OBn group. 
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Figure 3. Schematic representation of the NOEs seen for 2. 
 
Conformational analysis of 3. Peptidomimetic 3 also displayed C2 symmetry in DMSO-d6. 
Various NOEs LeuNH ↔ PheNH, PheNH ↔ IdacC3H (C4H), PheNH ↔ IdacC2H (C5H) and 
LeuNH ↔ IdacOH were observed along with sequential NOEs AlaNH ↔ LeuCαH, LeuNH ↔ 
PheCαH (Figure 4). Expanded ROESY spectrum of 3 with characteristic NOE connectivities is 
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shown in Figure 5. The temperature coefficient (∆δ/∆T) of –2.3 ppb.K–1 for leucine amide proton 
indicated its participation in intramolecular hydrogen bonding. The side chains of Leu and Phe 
appeared to take a predominant conformation about χ1, which is evident from JαH-βH = 9.8, JαH-β′H 
= 5.1 for Leu and JαH-βH = 10.4, JαH-β′H = 3.4 Hz for Phe. 
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Figure 4. Schematic representation of the proposed H-bonded structure of 3 with some of the 
prominent long-range NOEs seen in its ROESY spectrum. 
 
 
 
Figure 5. Expanded ROESY spectrum of 3 in DMSO-d6. 
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The structures sampled during the restrained MD calculations,8 using distance constraints 
based on the ROESY cross-peak intensities9 for 3 in DMSO-d6, are in agreement with the 
structure obtained from NMR studies. The two peptide-chains form a pseudo β-turn involving H-
bond between LeuNH and IdacOH. The central portions of these structures are fairly conserved 
with the variations localized mainly at the Leu side-chain (Figure 6). The five-membered sugar 
rings take twist conformations that are in agreement with the NMR data. 
 
 
 
Figure 6. Ten superimposed structures sampled during MD simulation studies for 3. Structures 
on left and right represent views from two different angles. 
 
Conformational analysis of 4. Similar to 3, organized structure was also observed in compound 
4. The ROESY spectrum of 4 in CDCl3 displayed C2 symmetry for half of the molecule. 
Characteristic NOEs like PheNH ↔ LeuNH, AlaNH ↔ LeuNH, LeuNH ↔ IdacC2H were 
observed along with the sequential connectivities PheNH ↔ IdacC2H, AlaNH ↔ LeuCαH and 
LeuNH ↔ PheCαH (Figure 7). Compound 4 showed restricted rotation for Leu χ1 with JαH-βH = 
9.0, and JαH-β′H = 5.7 Hz. For the Phe side-chain, there was no restricted rotation about χ1. 
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Figure 7. Schematic representation of some of the prominent long-range NOEs seen for 4 in 
CDCl3. 
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Conformational analysis of 5-8. Peptidomimetics 5-8 displayed perfect C2 symmetric structures 
in their NMR spectra in DMSO-d6. However, as the temperature coefficients of all the amide 
protons in these molecules were very high (Table 1), they were not studied for further structural 
details. The ROESY spectra of 6 and 8 did not show many long range NOEs (Figure 8) and 
definite structural information on their structures could not be obtained. This may partly be due 
to the additional methylene groups attached to the sugar ring. 
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Figure 8. Diagrammatic representations of some of the NOEs for 6 (left) and 8 (right) in DMSO-
d6. 
 
Discussion 
 
The large values (7.6-8.5 Hz) of 3JNH-αH for Phe and Leu in 3 and 4, and for Val in 2 were 
observed. Similarly, for the diamine peptidomimetics 5-8, the 3JNH-αHs were large (> 8 Hz) for 
Phe and Leu in 5 and 7, and for Val in 6 and 8, which correspond to a value of φ in the vicinity 
of –120°. The existence of a complete set of sequential CαH ↔ NH NOE connectivities, 
wherever possible, implied the propensity of structures with large population of conformers in 
the β-region of φ-ψ space (φ =–180° to –60° and ψ = 60° to 180°). The side-chains of Phe, Leu 
and Val point to the existence of large population of a single conformation in several of these 
peptides. For peptides 3, 4, 5, and 7, the LeuNH ↔ LeuCβH NOEs, stronger than the LeuNH ↔ 
LeuCβ′H NOEs, were observed. Further LeuCαH ↔ LeuCδH and LeuNH ↔ LeuCγH NOEs 
were also seen. Large JαH-βH of about 9 Hz and small JαH-β′H of about 5 Hz in Phe, Leu and Val 
further indicated restricted rotation about χ1. 
The observation of JH2-H3 = JH4-H5 = 3.5 Hz in 2, 3, and 4 and JH3-H4 ≈ 0 are consistent with a 
twist conformation of 43T (where 4 and 3 refer to C3 and C4, respectively) for the five-membered 
ring with C3 and C4 both being exo to the respective peptide chains. 
 
Conclusion 
 
The anticipated nucleation of the nine-membered β-turn like ring structures at both ends of these 
C2 symmetric assemblies involving identical intramolecular H-bonding, as observed in 1 
Issue in Honor of Prof. S. Swaminathan ARKIVOC 2005 (xi) 89-101 
ISSN 1424-6376 Page 96 ©ARKAT USA, Inc 
between LeuNH → sugarOH, was realised in some compounds. The observation of ∆δ/∆T for 
LeuNH being 2.3 and 2.8 in 3 and 4, respectively, support the formation of incipient 
intramolecular LeuNH → sugarOH hydrogen bonds in these molecules, relatively stronger in the 
former. In the diamine peptidomimetics, the absence of connectivities between sugar ring and the 
peptide sequences, along with the disappearance of the H-bonding character, which was 
consistently observed in the diacid-based molecules, indicate the deviation from the designed 
structure. Higher degree of freedom created in Idam and Mdam by the methylene group in the 
sugar ring might be responsible for the absence of any ordered structure. These observations 
reveal the importance of the constraints imparted in these structures for obtaining the designed 
reverse turn mimetics. 
In summary, introduction of C2 symmetric scaffolds 9-11 helped molecules 1-8 adopt C2 
symmetric structures and thus fulfilled the primary objective of our study. Although, these 
compounds did not show any activity towards HIV protease inhibition up to 2 mM inhibitor 
concentration,1 positioning of more appropriate residues at the P1/P1′ positions in these 
molecules will probably lead to substrates with improved biological activities.10 Further work is 
currently in progress. 
 
 
Experimental Section 
 
General Procedures. All reactions were carried out in oven or flame-dried glassware with 
magnetic stirring under nitrogen atmosphere using dry, freshly distilled solvents, unless 
otherwise noted. Reactions were monitored by thin layer chromatography (TLC) carried out on 
0.25 mm silica gel plates with UV light, I2, 7% ethanolic phosphomolybdic acid-heat and 2.5% 
ethanolic anisaldehyde (with 1% AcOH and 3.3% conc. H2SO4)-heat as developing agents. Silica 
gel finer than 200 mesh was used for flash column chromatography. Yields refer to 
chromatographically and spectroscopically homogeneous materials unless otherwise stated. IR 
spectra were recorded as neat liquids or KBr pellets. NMR spectra were recorded on 200, 300 
and 400 MHz spectrometers at room temperature of ~ 21 °C in CDCl3 using tetramethylsilane as 
internal standard or the solvent signal as secondary standard and the chemical shifts are shown in 
δ scales. Multiplicities of NMR signals are designated as s (singlet), d (doublet), t (triplet), q 
(quartet), br (broad), m (multiplet, for unresolved lines), etc.  13C NMR spectra were recorded 
with complete proton decoupling. Mass spectra were obtained under electron impact (EI), 
electron spray ionisation (ESI) and liquid secondary ion mass spectrometric (LSIMS) techniques. 
 
Synthesis of the peptides. The peptides were synthesized1,6b by conventional solution phase 
methods using 1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride (EDCI) and 1-
hydroxybenzotriazole (HOBt) as coupling agents and dry CH2Cl2 and/or amine-free dry DMF as 
solvents.11 While the tert-butoxycarbonyl (Boc) group was used for N-protection, the C-terminal 
was protected as a methyl ester (OMe). Deprotection of the former was done in TFA-CH2Cl2 
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(1:1) and saponification of the later was performed using LiOH in THF-MeOH-H2O. 
Deprotection of the Bn-protected compounds was done by hydrogenation using Pd(OH)2-C in 
MeOH. The final products were purified by silica gel column chromatography and fully 
characterized by spectroscopic methods before using them in the conformational studies. 
Selected physical data of 2. [α]D20 2.9° (c 0.24, CHCl3); IR (KBr) νmax 3282, 1639, 1546, 1359, 
1219, 1104, 771 cm–1; 1H NMR (DMSO-d6, 400 MHz) δ 8.51 (t,  2 H, J = 5.8 Hz, ArNH), 8.46 
(d, 2 H, J = 4.2 Hz, ArH), 8.08 (d, 2 H, JNH-αH  = 8.7 Hz, ValNH), 7.79 (d, 2 H, JNH-αH = 8.3 Hz, 
PheNH), 7.71 (dt, 2 H, J = 1.7, 7.7, 7.7 Hz, ArH), 7.30-7.06 (m, 24 H, ArH), 4.76-4.69 (m, 4 H, 
PhCH2), 4.71 (ddd, 2 H, JNH-αH = 8.3, JβH-αH = 8.4, JβH-αH = 4.4 Hz, PheCαH), 4.53 (d, 2 H, J = 
3.5 Hz, IdacC2H, C5H), 4.38-4.28 (m, 2 H, ArCH2), 4.19 (dd, 2 H, JαH-βH = 7.4, JNH-αH = 8.7 Hz, 
ValCαH), 4.13 (t, 2 H, J = 3.5 Hz, IdacC3H, C4H), 3.05 (dd, 2 H, JβH-αH = 4.4, JβH-β´H = 13.7 Hz, 
PheCβ´H), 2.88 (dd, 2 H, JβH-αH = 8.4, JβH-β´H = 13.7 Hz, PheCβH), 1.95 (m, 2 H, ValCβH), 0.83 
(d, 12 H, J = 6.7 Hz, Val CγCH3, ValCγ´CH3); MS (LSIMS) m/z (%) 1045 (54) [M + H]+, 1067 
(24) [M + Na]+. 
Selected physical data of 3. [α]D20 –12.8° (c 0.52, CHCl3); IR (KBr) νmax 3410, 2920, 1790, 
1740, 1540, 1200, 960, 720 cm–1; 1H NMR (DMSO-d6, 500 MHz) δ 8.09 (d, 2 H, JNH-αH = 
6.8 Hz, AlaNH), 8.07 (d, 2 H, JNH-αH = 8.5 Hz, PheNH), 7.72 (d, 2 H, JNH-αH = 8.2 Hz, LeuNH), 
7.28-7.19 (m, 10 H, ArH), 5.96 (d, 2 H, J = 2.8 Hz, OH), 4.56 (d, 2 H, J = 3.5 Hz, IdacC2H, 
C5H), 4.50 (ddd, 2 H, JαH-βH = 10.4, JNH-αH = 8.5, JαH-β´H 3.4 Hz, PheCαH), 4.28 (ddd, 2 H, JNH-αH 
= 8.2, JαH-βH = 9.8, JαH-β´H = 5.1, LeuCαH), 4.23 (m, 2 H, AlaCαH), 4.16 (dd, 2 H, J = 2.8, 
3.5 Hz, IdacC3H, C4H), 3.60 (s, 6 H, JNH-αH = 8.2, OCH3), 3.19 (dd, 2 H, JαH-β′H = 3.4, JβH-β′H = 
14.1 Hz, PheCβ′H), 2.96 (dd, 2 H, JαH-βH = 10.4, JβH-β′H = 14.1 Hz, PheCβH), 1.63 (m, 2 H, 
LeuCγH), 1.44 (ddd, 2 H, JαH-β′H = 5.1, Jβ′H-γH = 8.6, JβH-β′H  = 13.5 Hz, LeuCβ′H), 1.38 (ddd, 2 H, 
JαH-βH = 9.8, JβH-γH = 5.6, JβH-β′H = 13.5 Hz, LeuCβH), 1.30 (d, 6 H, JαH-βCH3 = 6.4 Hz, AlaCβCH3) 
0.89 (d, 6 H, JγH-δH = 7.2 Hz, LeuCδCH3), 0.80 (d, 6 H, JγH-δ′H = 7.2 Hz, LeuCδ′CH3); 13C NMR 
(CDCl3, 125 MHz) δ 172.92, 172.25, 170.51, 169.47, 135.79, 128.94, 128.91, 127.51, 83.26, 
77.92, 54.19, 52.43, 51.35, 48.46, 40.39, 36.55, 24.48, 22.89, 21.72, 17.49; MS (LSIMS) m/z (%) 
883 (100) [M + H]+, 905 (80) [M + Na]+. 
Selected physical data of 4. 1H NMR (CDCl3, 500 MHz) δ 7.32-7.18 (m, 18 H, ArH), 7.06-7.01 
(m, 2 H, ArH), 6.94 (d, 2 H, JNH-αH = 7.8 Hz, PheNH), 6.66 (d, 2 H, JNH-αH = 7.3 Hz, AlaNH), 
6.28 (d, 2 H, JNH-αH = 8.3 Hz, LeuNH), 4.61 (d, 2 H, J = 3.5 Hz, Idac-C2H, C5H), 4.50 (ddd, 2 H, 
PheCαH), 4.42 (m, 2 H, AlaCαH), 4.34 (ddd, 2 H, JαH-βH = 9.0, JαH-β′H = 5.7 Hz, LeuCαH), 4.05 
(d, 2 H, J = 3.5 Hz, IdacC3H, C4H), 4.34 (ABq, 4 H, J = 12.9 Hz, PhCH2), 3.72 (s, 6 H, OCH3), 
3.28 (dd, 2 H, JαH-β′H = 6.2, JβH-β′H  = 13.8 Hz, PheCβ′H),  3.14 (dd, 2 H, JαH-βH = 10.4, JβH-β′H  = 
14.1 Hz, PheCβH), 1.57 (ddd, 2 H, JαH-β′H = 5.9, Jβ′H-γH = 8.2, JβH-β′H  = 13.9 Hz, LeuCβ′H), 1.35 
(d, 6 H, JαH-βH = 7.3 Hz, AlaCβCH3), 1.29 (m, 2 H, LeuCγH), 1.12 (ddd, 2 H, JαH-βH = 8.9, JβH-γH  
= 5.7, JβH-β′H  = 13.9 Hz, LeuCβH), 0.79 (d, 6 H, JγH-δH = 6.5 Hz, LeuCδCH3), 0.75 (d, 6 H, JγH-δ′H 
= 6.5 Hz, LeuCδ′CH3).  
Selected physical data of 5. [α]D20 –43.1° (c 0.5, CHCl3), IR (KBr) νmax 3410, 3350, 2910, 2900, 
1660, 1640, 1540, 1160, 1100, 1075, 763, 712 cm–1; 1H NMR (DMSO-d6, 400 MHz) δ 8.06 (t, 2 
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H, J = 6.2 Hz, IdamNH), 7.71 (d, 2 H, JNH-αH 8.1 Hz, PheNH), 7.28-7.14 (m, 10 H, ArH), 6.88 
(d, 2 H, JNH-αH = 8.3 Hz, LeuNH), 5.06 (d, 2 H, J = 4.5 Hz, OH), 4.52 (ddd, 2 H, JNH-αH = 8.1, 
JαH-β´H = 5.0, JαH-βH = 8.9 Hz, PheCαH), 3.93 (dt, 2 H, J = 3.0, 6.2, 6.2 Hz, IdamC2H, C5H), 3.86 
(ddd, 2 H, JNH-αH = 8.3, JαH-βH = 9.9, JαH-β´H 5.2 Hz, LeuCαH), 3.83 (dd, 2 H, J = 3.0, 4.5 Hz, 
IdamC3H, C4H), 3.25 (dt, 2 H, J = 6.2, 6.2, 13.6 Hz, IdamC1H, C6H), 3.12 (dt, 2 H, J = 6.2, 6.2, 
13.6 Hz, IdamC1H´, C6H´), 2.94 (dd, 2 H, JαH-β´H = 5.0, JβH-β´H  = 13.7 Hz, PheCβ´H), 2.80 (dd, 2 
H, JαH-βH = 8.9, JβH-β´H = 13.7 Hz, PheCβH), 1.46 (m, 2 H, LeuCγH), 1.37 (s, 18 H, Boc), 1.31 (m, 
2 H, JαH-βH = 9.9, JβH-γH = 5.4, JβH-β´H = 13.5 Hz, LeuCβH), 1.22 (m, 2 H, JαH-β´H = 5.2, Jβ´H-γH = 
8.5, JβH-β´H = 13.5 Hz, LeuCβ´H), 0.82 (d, 6 H, JδCH3-γH = 6.6 Hz, LeuCδCH3 ), 0.78 (d, 6 H, 
Jδ´CH3-γH = 6.6 Hz, LeuCδCH3 ); 13C NMR (CDCl3, 125 MHz) δ 172.86, 172.35, 155.89, 136.23, 
129.24, 128.57, 126.97, 80.32, 79.36, 75.86, 53.94, 53.56, 41.04, 38.08, 37.91, 28.23, 24.66, 
22.85, 21.74; MS (LSIMS) m/z 884 (100) [M + H]+, 906 (90) [M + Na]+. 
Selected physical data of 6. [α]D20 –23.3° (c 0.5, CHCl3); 1H NMR (DMSO-d6, 500 MHz) δ 
8.04 (t, 2 H, J = 6.8 Hz, IdamNH), 7.85 (d, 2 H, JNH-αH = 8.4 Hz, PheNH), 7.24-7.14 (m, 10 H, 
ArH), 6.64 (d, 2 H, JNH-αH = 8.4 Hz, ValNH), 5.05(s, 2 H, J = 3.6 Hz, OH), 4.56 (ddd, 2 H, JNH-αH 
= 8.4, JαH-β’H = 5.1, JαH-βH = 9.2 Hz, PheCαH), 3.91 (dt, 2 H, J = 2.8, 6.8, 6.8 Hz, IdamC2H, 
C5H), 3.82 (dd, 2 H, J = 2.8, 3.6 Hz, IdamC3H, C4H), 3.70 (dd, 2 H, JNH-αH = 8.4 Hz, JαH-βH = 
6.8 Hz, ValCαH), 3.24 (ddd, 2 H, J = 5.8, 6.8, 13.6 Hz, IdamC1H, C6H), 3.12 (dt, 2 H, J = 5.6, 
6.8, 13.6 Hz, IdamC1H´, C6H´), 2.94 (dd, 2 H, JαH-β´H = 5.1, JβH-β´H = 13.7 Hz, PheCβ´H), 2.79 
(dd, 2 H, JαH-βH = 9.2, JβH-β´H = 13.7 Hz, PheCβH), 1.81(m, 2 H, ValCβH), 1.37 (s, 18 H, Boc), 
0.71 (d, 6 H, JβH-γCH3 = 6.8 Hz, ValCγCH3), 0.67 (d, 6 H, JβH-γCH3 = 6.8 Hz, ValCγ´CH3 ); 13C 
NMR (CDCl3, 125 MHz) δ 171.38, 170.87, 155.27, 137.47, 129.11, 127.91, 126.15, 78.53, 
78.06, 75.84, 59.99, 53.48, 38.29, 37.92, 30.36, 28.11, 19.02, 18.05; MS (LSIMS) m/z (%) 856 
(100) [M + H]+, 878 (40) [M + Na]+. 
Selected physical data of 7. [α]D20 –34.8° (c 0.5, CHCl3); IR (Neat) νmax 3400, 2970, 1680, 
1635, 1219, 1530, 1160 cm–1; 1H NMR (DMSO-d6, 500 MHz) δ 8.10 (t, 2 H, J = 6.2 Hz, 
MdamNH), 7.66 (d, 2 H, JNH-αH = 8.1 Hz, PheNH), 7.13-7.25 (m, 10 H, ArH), 6.89 (d, JNH-αH = 
8.6 Hz, LeuNH), 5.18 (d, 2 H, J = 4.0 Hz, OH), 4.56 (ddd, 2 H, JNH-αH = 8.1 Hz,  JαH-βH = 9.5, 
JαH-β´H = 4.7 Hz, PheCαH), 3.86 (ddd, 2 H, J = 6.2, 8.6, 9.7 Hz, MdamC2H, C5H), 3.76 (ddd, 2 
H, JNH-αH = 8.6 Hz, JαH-βH = 9.7, JαH-β´H = 5.2 Hz, LeuCαH), 3.71 (ddd, 2 H, J = 2.4, 4.0, 8.6 Hz, 
MdamC3H, C4H), 3.28 (m, 2 H, MdamC1H, C6H), 3.20 (dt, 2 H, J = 6.2, 6.2, 13.8 Hz, 
MdamC1H´, C6H´), 2.97 (dd, 2 H, JαH-β´H = 4.7, JβH-β´H = 13.7 Hz, PheCβ´H), 2.78 (dd, 2 H, JαH-
βH = 9.5, JβH-β´H = 13.7 Hz, PheCβH), 1.44 (m, 2 H, LeuCγH), 1.37 (s, 18 H, Boc), 1.31 (m, 2 H, 
JαH-βH = 9.7, JβH-γH = 5.5, JβH-β´H = 13.5 Hz, LeuCβH), 1.20 (m, 2 H, JαH-β´H = 5.4,  Jβ´H-γH = 8.9, 
JβH-β´H = 13.5 Hz, LeuCβ´H), 0.82 (d, 6 H, JδCH3-γH = 6.6 Hz, LeuCδCH3 ), 0.77 (d, 6 H, Jδ´CH3-γH 
= 6.6 Hz, LeuCδ´CH3 ); 13C NMR (CDCl3, 125 MHz) δ 173.25, 171.90, 155.88, 136.66, 129.35, 
128.45, 126.78, 81.31, 80.19, 78.45, 54.44, 53.49, 41.22, 38.07, 28.28, 24.60, 22.94, 21.74; MS 
(LSIMS) m/z (%) 783 (82) [M + H – C5H8O2]+, 883 (48) [M + H]+, 905 (100) [M + Na]+. 
Selected physical data of 8. [α]D20 29.5° (c 0.55, CHCl3); IR (Neat) νmax 3400, 3300, 2995, 
1685, 1640, 1580, 1540, 1200 cm–1; 1H NMR (DMSO-d6, 500 MHz) δ 8.07 (t, 2 H, J = 6.3 Hz, 
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MdamNH), 7.81 (d, 2 H, JNH-αH = 8.7 Hz, PheNH), 7.23-7.14 (m, 6 H, ArH), 6.65 (d, 2 H, JNH-αH 
= 9.2 Hz, ValNH), 5.17 (d, 2 H, J = 3.9 Hz, OH), 4.60 (ddd, 2 H, JNH-αH = 8.7, JαH-β´H = 9.7, JαH-
β´H = 4.3 Hz, PheCαH), 3.77-3.70 (m, 4 H, MdamC2H, C3H, C4H, C5H), 3.69 (dd, 2 H, JNH-αH = 
9.2, JαH-βH = 6.8 Hz, ValCαH), 3.27 (dt, 2 H, J = 6.3, 6.3 13.2 Hz, MdamC2H, C6H), 3.19 (dt, 2 
H, J = 6.3, 6.3,13.2 Hz, MdamC1H´, C6H´), 2.97 (dd, 2 H, JαH-β´H = 4.3, JβH-β´H = 13.7 Hz, 
PheCβ´H), 2.77 (dd, 2 H, JαH-β´H = 9.7, JβH-β´H  = 13.7 Hz, PheCβH), 1.79(m, 2 H, ValCβH), 1.37 
(s, 18 H, Boc), 0.69 (d, 6 H, JβH-γCH3 = 6.8 Hz, ValCγCH3), 0.64 (d, 2 H, JβH-γCH3 = 6.8 Hz, 
ValCγ´CH3 ); 13C NMR (DMSO-d6, 125 MHz) δ 171.10, 170.86, 155.27, 137.64, 129.18, 127.87, 
126.11, 82.12, 78.18, 78.08, 60.10, 53.41, 41.10, 38.13, 30.41, 28.13, 19.04, 18.08; MS (LSIMS) 
m/z (%) 755 (22) [M + H – C5H8O2]+, 855 (15) [M + H]+, 877 (18) [M + Na]+. 
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